

## COMMUNIQUÉ FROM ANNUAL GENERAL MEETING IN EMP LICURE AB (PUBL)

**Today, Emplicure AB (publ) held its Annual General Meeting, whereby the following resolutions were made.**

### **Adoption of the income statement and the balance sheet: allocation of result**

The Annual General Meeting adopted the income statement and balance sheet for the company and for the group in accordance with the submitted accounting documents and resolved, that the accumulated funds shall be treated in accordance with the proposal in the annual report. The resolution entails that no dividend is paid for the financial year 2022.

### **Discharge from liability**

The Annual General Meeting resolved to discharge the board of directors, the CEO and the previous CEO Torbjörn Walker Larsson from liability for the financial year 2022.

### **The board of directors and the remuneration of the board of directors**

The ordinary board members Gunilla Ekström, Gisela Sitbon and Johan Wieslander were re-elected and Jonas Ekblom and Anders Peteri were elected as ordinary board members, each for a term of office extending to the end of the next Annual General Meeting. Gisela Sitbon was re-elected as chairperson of the board of directors.

The Annual General Meeting resolved on remuneration of the board of directors as follows: SEK 270,000 for the chairperson and SEK 125,000 for each of the members of the board of directors.

### **The auditor and the remuneration for the auditor**

The Annual General Meeting resolved to elect Finnhammars Revisionsbyrå with Per-Olov Strand as auditor in charge for the period until the end of the next annual general meeting of the shareholders. The remuneration to the auditor shall be paid against approved invoice.

### **The Nomination Committee and Instructions for the Nomination Committee**

The Nomination Committee's proposal of principles for the establishment of a Nomination Committee were approved by the Annual General Meeting. In addition, the Nomination Committee's proposal on adoption of instructions for the work of the Nomination Committee ahead of the Annual General Meeting 2024 were approved.

### **Resolution on authorisation to issue shares**

The Annual General Meeting authorised the board of directors, whether on one or several occasions, during the period up to the next annual general meeting, to increase the company's share capital by issue of new shares. The board of directors is authorised to adopt resolutions on issues of shares with or without deviation from the shareholders' pre-emption rights.

An issue in accordance with the authorisation shall be on market conditions. The board of directors is authorised to decide the terms in general for share issues resolved in accordance with this authorisation and who should be entitled to subscribe for the shares. The reason for that the board of directors should be able to resolve on issues of new shares with deviation from the shareholders pre-emption rights is to give the board of directors the possibility to resolve on directed issues if the board of directors deems that it is the best alternative to secure financing to meet the company's financial needs.

The Annual General Meeting authorised the managing director to make such minor adjustments to the resolution that may be necessary in connection with the registration with the Swedish Companies Registration Office and Euroclear Sweden AB.



*Emplicure develops new and innovative products by combining existing and approved active substances with advanced materials science within ceramic biomaterials. The product portfolio is focused on chronic pain and on abuse-deterrent formulations. The subsidiary Amplicon AB develops consumer products with oral nicotine as the first product. The share is listed on Nasdaq First North Growth Market (EMPLI). Read more at [www.emplicure.com](http://www.emplicure.com)*

*The information was released for public disclosure, through agency of the contact person below, on June 13, 2023 at 11.12 p.m CEST.*

For more information, please contact:

**Håkan Engqvist**

CEO

Phone: +46 (0) 702 569 500

Email: [hakan.engqvist@emplicure.com](mailto:hakan.engqvist@emplicure.com)

**Erik Magnusson**

CFO

Phone: +46 (0)70 856 52 45

Email: [erik.magnusson@emplicure.com](mailto:erik.magnusson@emplicure.com)

**Certified Adviser**

Certified Adviser is Erik Penser Bank



*Emplicure develops new and innovative products by combining existing and approved active substances with advanced materials science within ceramic biomaterials. The product portfolio is focused on chronic pain and on abuse-deterrent formulations. The subsidiary Amplicon AB develops consumer products with oral nicotine as the first product. The share is listed on Nasdaq First North Growth Market (EMPLI). Read more at [www.emplicure.com](http://www.emplicure.com)*